SAR103168: a tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias

References

• Estey E, Döhner H. Acute myeloid leukemia. N Engl J Med 2006;368:1894–1907.
   Google Scholar
• Howlader N, Noone AM, Krapcho M, et al., editors. SEER Cancer Statistics Review, 1975-2008, National Cancer Institute, Bethesda, MD, based on November 2010 SEER data submission, posted to the SEER web site, 2011. Available from:http://seer.cancer.gov/csr/1975_2008/
   Google Scholar
• Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358:1909–1918.
   PubMed Web of Science ®Google Scholar
• Ozawa Y, Williams AH, Estes ML, et al. Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT). Leuk Res 2008;32:893–903.
   PubMed Web of Science ®Google Scholar
• Okamoto M, Hayakawa F, Miyata Y, et al. Lyn is an important component of the signal transduction pathway specific to FLT3/ ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD. Leukemia 2007;21:403–410.
   PubMed Web of Science ®Google Scholar
• Dos Santos C, Demur C, Bardet V, et al. A critical role for Lyn in acute myeloid leukemia. Blood 2008;11:2269–2279.
   Web of Science ®Google Scholar
• Hayakawa F, Towatari M, Kiyoi H, et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 2000;19:624–631.
   PubMed Web of Science ®Google Scholar
• Mizuki M, Fenski R, Halfter H, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 2000;96:3907–3914.
   PubMed Web of Science ®Google Scholar
• Schepers H, Van Gosliga D, Wierenga AT, et al. STAT5 is required for long-term maintenance of normal and leukemic human stem/progenitor cells. Blood 2007;110:2880–2888.
   PubMed Web of Science ®Google Scholar
• Fathi AT, Grant S, Karp JE. Exploiting cellular pathways to develop new treatment strategies for AML. Cancer Treat Rev 2010;36:142–150.
   PubMed Web of Science ®Google Scholar
• Grant S. New agents for AML and MDS. Best Pract Res Clin Haematol 2009;22:501–507.
   PubMed Web of Science ®Google Scholar
• Stone RM. Novel therapeutic agents in acute myeloid leukemia. Exp Hematol 2007;35:163–166.
   PubMed Web of Science ®Google Scholar
• Bao T, Smith BD, Karp JE. New agents in the treatment of acute myeloid leukemia: a snapshot of signal transduction modulation. Clin Adv Hematol Oncol 2005;3:287–296.
   PubMedGoogle Scholar
• Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999;94:3717–3721.
   PubMed Web of Science ®Google Scholar
• Wakabayashi M, Miwa H, Shikami M, et al. Autocrine pathway of angiopoietins-Tie2 system in AML cells: association with phosphatidyl-inositol 3 kinase. Hematol J. 2004;5:353–360.
   PubMedGoogle Scholar
• Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730–737.
   PubMed Web of Science ®Google Scholar
• Dick JE. Stem cell concepts renew cancer research. Blood 2008; 112:4793–4807.
   PubMed Web of Science ®Google Scholar
• Trumpp A, Wiestler OD. Mechanisms of disease: cancer stem cells—targeting the evil twin. Nat Clin Pract Oncol 2008;5:337–347.
   PubMedGoogle Scholar
• Récher C, Beyne-Rauzy O, Demur C, et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005;105:2527–2534.
   PubMed Web of Science ®Google Scholar
• Fiebig HH, Maier A, Burger AM. Clonogenic assay with established human tumours xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer 2004;40:802–820.
   PubMed Web of Science ®Google Scholar
• Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of human genome. Science 2002;198:1912–1934.
   Web of Science ®Google Scholar
• Karp JE, Smith BD, Gojo I, et al. Phase II trial of tipifranib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin Cancer Res 2008;14:3077–3082.
   PubMed Web of Science ®Google Scholar
• Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel abl kinase inhibitor. Science 2004;305:399–401.
   PubMed Web of Science ®Google Scholar
• Miranda MB, Johnson DE. Signal transduction pathways that contribute to myeloid differentiation. Leukemia 2007;21:1363–1377.
   PubMed Web of Science ®Google Scholar
• Mitina O, Warmuth M, Krause G, et al. Src family tyrosine kinases phosphorylate Flt3 on juxtamembrane tyrosines and interfere with receptor maturation in a kinase-dependent manner. Ann Hematol 2007;86:777–785.
   PubMed Web of Science ®Google Scholar
• Sampson M, Zhu QS, Corey SJ. Src kinases in G-CSF receptor signalling. Front Biosci 2007;12:1463–1474.
   PubMed Web of Science ®Google Scholar
• Robinson LJ, Xue J, Corey SJ. Src family kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations. Exp Hematol 2005;33:469–479.
   PubMed Web of Science ®Google Scholar
• Rao AV, Valk PJM, Metzeler KH, et al. Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. J Clin Oncol 2009;27:5580–5586.
   PubMed Web of Science ®Google Scholar
• Hayakawa F, Naoe T. SFK–STAT pathway: an alternative and important way to malignancies. Ann NY Acad Sci 2006;1086:213–222.
   PubMed Web of Science ®Google Scholar
• Choudhary C, Brandts C, Schwable J, et al. Activation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood 2007;110:370–374.
   PubMed Web of Science ®Google Scholar
• Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-Chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658–6661.
   PubMed Web of Science ®Google Scholar
• Johnson FM, Saigal B, Talpaz M, et al. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non small cell, lung cancer cells. Clin Cancer Res 2005;11:6924–6932.
   PubMed Web of Science ®Google Scholar
• Nam S, Kim D, Cheng JQ, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005;65:9185–9189.
   PubMed Web of Science ®Google Scholar